Thrombocytopenic purpura - eltrombopag - NICE TAG TA293

This guidance replaces NICE technology appraisal guidance 205 issued in October 2010.

1.1 Eltrombopag is recommended as an option for treating adults with chronic immune (idiopathic) thrombocytopenic purpura, within its marketing authorisation (that is, in adults who have had a splenectomy and whose condition is refractory to other treatments, or as a second-line treatment in adults who have not had a splenectomy because surgery is contraindicated), only if:

• their condition is refractory to standard active treatments and rescue therapies, or

• they have severe disease and a high risk of bleeding that needs frequent courses of rescue therapies
  and

• the manufacturer provides eltrombopag with the discount agreed in the patient access scheme.

1.2 People currently receiving eltrombopag whose disease does not meet the criteria in 1.1 should be able to continue treatment until they and their clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/TA293